Symbols

ANAB

AnaptysBio·NASDAQ

--(--)

Signals Analysis

Bullish signal 7

Bearish signal 1

Consensus Rating "Strong Buy"

Bearish Engulfing

Ample Liquidity

High Gross Profit Margin

Significant Net Income Growth

High Cash/net Profit Ratio

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ANAB

Anaptysbio, Inc.

A clinical-stage biotechnology company focused on innovative immunology therapeutics

Industry

Biological Technology

Established Date

Listing Date

01/26/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

104

Fiscal Year Ends

12-31

Website

www.anaptysbio.com

Security Type

Common stock

Office address

10770 Wateridge Circle, Suite 210, San Diego, CA 92121

Business

Introduction

AnaptysBio, Inc., established in Delaware in November 2005. The company is a clinical-stage biotechnology company focused on providing innovative immunotherapies for autoimmune and inflammatory diseases. The company's clinical-stage R&D pipeline includes rosnilimab, a selective pathogenic T-cell scavenger, which has completed a Phase IIb clinical trial for the treatment of moderate to severe rheumatoid arthritis (RA). In addition, its R&D pipeline includes ANB033, a CD122 antagonist currently undergoing Phase Ib clinical trials for the treatment of celiac disease (CeD) and eosinophilic esophagitis (EoE); and ANB101, a BDCA 2 modulator currently undergoing Phase Ia clinical trials. AnaptysBio has also discovered a variety of therapeutic antibodies through financial collaborations and licensed them to GSK, including licensing the PD-1 antagonist Jemperli (dostarlimab-gxly) to GSK and the IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals Inc.

Company Financials

EPS

ANAB has released its 2025 Q4 earnings. EPS was reported at 1.58, versus the expected 0.92, beating expectations. The chart below visualizes how ANAB has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ANAB has released its 2025 Q4 earnings report, with revenue of 108.25M, reflecting a YoY change of 151.08%, and net profit of 49.61M, showing a YoY change of 327.75%. The Sankey diagram below clearly presents ANAB's revenue sources and cost distribution.